AUD 0.01
(0.0%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 | 12.43 Million AUD | -15.26% |
2023 | 14.66 Million AUD | 3.87% |
2022 | 14.12 Million AUD | -3.15% |
2021 | 14.58 Million AUD | 29.05% |
2020 | 11.29 Million AUD | 65.27% |
2019 | 6.83 Million AUD | 62.11% |
2018 | 4.21 Million AUD | -42.24% |
2017 | 7.3 Million AUD | 1.49% |
2016 | 7.19 Million AUD | 5.11% |
2015 | 6.84 Million AUD | -3.63% |
2014 | 7.1 Million AUD | -47.9% |
2013 | 13.63 Million AUD | 52.28% |
2012 | 8.95 Million AUD | -15.32% |
2011 | 10.57 Million AUD | -40.33% |
2010 | 17.71 Million AUD | 207.77% |
2009 | 5.75 Million AUD | 13.86% |
2008 | 5.05 Million AUD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 FY | 12.43 Million AUD | -15.26% |
2024 Q2 | 13.14 Million AUD | 0.0% |
2024 Q4 | 12.43 Million AUD | 0.0% |
2023 Q2 | 15.62 Million AUD | 0.0% |
2023 Q4 | 14.66 Million AUD | 0.0% |
2023 FY | 14.66 Million AUD | 3.87% |
2022 Q2 | 14.9 Million AUD | 0.0% |
2022 Q4 | 14.12 Million AUD | 0.0% |
2022 FY | 14.12 Million AUD | -3.15% |
2021 FY | 14.58 Million AUD | 29.05% |
2021 Q4 | 14.58 Million AUD | 0.0% |
2021 Q2 | 11.21 Million AUD | 0.0% |
2020 Q2 | 11.45 Million AUD | 0.0% |
2020 FY | 11.29 Million AUD | 65.27% |
2020 Q4 | 11.29 Million AUD | 0.0% |
2019 FY | 6.83 Million AUD | 62.11% |
2019 Q4 | 6.83 Million AUD | 0.0% |
2019 Q2 | 4.68 Million AUD | 0.0% |
2018 FY | 4.21 Million AUD | -42.24% |
2018 Q4 | 4.21 Million AUD | 0.0% |
2018 Q2 | 4.6 Million AUD | 0.0% |
2017 Q4 | 7.3 Million AUD | 0.0% |
2017 FY | 7.3 Million AUD | 1.49% |
2017 Q2 | 6.96 Million AUD | 0.0% |
2016 Q2 | 6.75 Million AUD | 0.0% |
2016 FY | 7.19 Million AUD | 5.11% |
2016 Q4 | 7.19 Million AUD | 0.0% |
2015 Q4 | 6.84 Million AUD | 0.0% |
2015 Q2 | 7.34 Million AUD | 0.0% |
2015 FY | 6.84 Million AUD | -3.63% |
2014 Q2 | 14.06 Million AUD | 0.0% |
2014 FY | 7.1 Million AUD | -47.9% |
2014 Q4 | 7.1 Million AUD | 0.0% |
2014 Q3 | 7.1 Million AUD | -49.51% |
2014 Q1 | 14.06 Million AUD | 3.2% |
2013 Q2 | 10.8 Million AUD | 0.0% |
2013 Q1 | 10.8 Million AUD | 20.72% |
2013 Q4 | 13.63 Million AUD | 0.0% |
2013 FY | 13.63 Million AUD | 52.28% |
2013 Q3 | 13.63 Million AUD | 26.14% |
2012 FY | 8.95 Million AUD | -15.32% |
2012 Q4 | 8.95 Million AUD | 0.0% |
2011 Q4 | 10.57 Million AUD | 0.0% |
2011 FY | 10.57 Million AUD | -40.33% |
2010 FY | 17.71 Million AUD | 207.77% |
2010 Q4 | 17.71 Million AUD | 0.0% |
2009 Q4 | 5.75 Million AUD | 0.0% |
2009 FY | 5.75 Million AUD | 13.86% |
2008 Q4 | 5.05 Million AUD | 0.0% |
2008 FY | 5.05 Million AUD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
AdAlta Limited | 5.57 Million AUD | -123.042% |
Acrux Limited | 8.96 Million AUD | -38.683% |
Race Oncology Limited | 20.22 Million AUD | 38.552% |
Biome Australia Limited | 8.27 Million AUD | -50.181% |
Botanix Pharmaceuticals Limited | 112.46 Million AUD | 88.948% |
BTC Health Limited | 5.14 Million AUD | -141.418% |
Chimeric Therapeutics Limited | 15.27 Million AUD | 18.614% |
CSL Limited | 56.93 Billion AUD | 99.978% |
Clarity Pharmaceuticals Ltd | 154.62 Million AUD | 91.961% |
Clinuvel Pharmaceuticals Limited | 231.12 Million AUD | 94.622% |
EZZ Life Science Holdings Limited | 25.55 Million AUD | 51.353% |
Hexima Limited | 2.26 Million AUD | -447.824% |
Immutep Limited | 147.44 Million AUD | 91.57% |
Neuren Pharmaceuticals Limited | 247.97 Million AUD | 94.987% |
Noxopharm Limited | 6.78 Million AUD | -83.234% |
Prescient Therapeutics Limited | 20.39 Million AUD | 39.047% |
Radiopharm Theranostics Limited | 72.03 Million AUD | 82.745% |
Starpharma Holdings Limited | 36.81 Million AUD | 66.235% |
Tissue Repair Ltd | 19.38 Million AUD | 35.893% |
Biotron Limited | 493.47 Thousand AUD | -2418.896% |
Alterity Therapeutics Limited | 19.22 Million AUD | 35.34% |
Anatara Lifesciences Ltd | 1.67 Million AUD | -643.687% |
Bio-Gene Technology Limited | 3.15 Million AUD | -293.41% |
Zelira Therapeutics Limited | 5.18 Million AUD | -139.806% |
Patrys Limited | 4.16 Million AUD | -198.688% |
Orthocell Limited | 26.61 Million AUD | 53.297% |
Imugene Limited | 151.39 Million AUD | 91.79% |
PYC Therapeutics Limited | 91.23 Million AUD | 86.376% |
Proteomics International Laboratories Limited | 10.87 Million AUD | -14.299% |
Cynata Therapeutics Limited | 8.38 Million AUD | -48.185% |
Arovella Therapeutics Limited | 13.28 Million AUD | 6.432% |
Nanollose Limited | 241.95 Thousand AUD | -5037.465% |
Invex Therapeutics Ltd | 6.12 Million AUD | -103.105% |
NeuroScientific Biopharmaceuticals Limited | 5.43 Million AUD | -128.669% |
Amplia Therapeutics Limited | 14.84 Million AUD | 16.268% |
Island Pharmaceuticals Limited | 2.56 Million AUD | -384.706% |
Nyrada Inc. | 5.9 Million AUD | -110.421% |
Telix Pharmaceuticals Limited | 398.3 Million AUD | 96.879% |
Dimerix Limited | 32.07 Million AUD | 61.251% |
PharmAust Limited | 11.12 Million AUD | -11.733% |
AnteoTech Limited | 9.38 Million AUD | -32.501% |
Paradigm Biopharmaceuticals Limited | 27.39 Million AUD | 54.619% |
Recce Pharmaceuticals Ltd | 6.36 Million AUD | -95.148% |
Avecho Biotechnology Limited | 7.31 Million AUD | -69.827% |
Actinogen Medical Limited | 21.31 Million AUD | 41.675% |
Immuron Limited | 15.54 Million AUD | 20.063% |
Argenica Therapeutics Limited | 16.37 Million AUD | 24.103% |